SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject2/2/2004 7:17:58 PM
From: mopgcw   of 598
 
Tularik, Inc. EPS (FY Dec) 2004E ($1.73), 2005E ($1.92) In-Line/Neutral
(TLRK) $17.29
The Goldman Sachs Biotechnology Team will host a conference call on Thursday,
February 5, at 10 AM EDT with senior management of Tularik, who will provide an
overview of the cancer platform and candidates in the pipeline. The call is for
INSTITUTIONAL INVESTORS only. To participate, please dial 800-203-4101
(US) or 952-556 2859 (Int 'l). Replay 800-615-3210 (US) or 703-326-3210 (Int 'l),
5076453 (passcode).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News